SEC Comment Letter for NYMOX PHARMACEUTICAL CORP (NYMXF) (CIK 0001018735) (NYMXF) — May 14, 2021
NYMOX PHARMACEUTICAL CORP (NYMXF) (CIK 0001018735)
Date: May 14, 2021 · CIK: 0001018735 · Accession: 0000000000-21-006167
AI Filing Summary & Sentiment
File numbers found in text: 333-256024
Letter
United States securities and exchange commission logo May 14, 2021 Paul Averback Chief Executive Officer NYMOX PHARMACEUTICAL CORP Bay & Deveaux Streets Nassau, The Bahamas Re:NYMOX PHARMACEUTICAL CORP Registration Statement on Form F-3 Filed May 12, 2021 File No. 333-256024 Dear Dr. Averback: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tom Kluck at 202-551-3233 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: M. Richard Cutler
Show Raw Text
United States securities and exchange commission logo
May 14, 2021
Paul Averback
Chief Executive Officer
NYMOX PHARMACEUTICAL CORP
Bay & Deveaux Streets
Nassau, The Bahamas
Re:NYMOX PHARMACEUTICAL CORP
Registration Statement on Form F-3
Filed May 12, 2021
File No. 333-256024
Dear Dr. Averback:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tom Kluck at 202-551-3233 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: M. Richard Cutler